Black Lung Disease Global Market Report 2024

The global black lung disease market has grown rapidly in recent years. It will grow from $8.44 billion in 2023 to $9.66 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to coal mining industry growth, awareness and education, compensation and benefits, legislative and legal developments.

The global black lung disease market is expected to see rapid growth in the next few years. It will grow to $16.7 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to public health initiatives, medical advancements, increasing treatment options, advocacy and support organizations. Major trends in the forecast period include advanced diagnostic techniques, research and prevention, healthcare access, technological advancements.

The growth of the black lung disease market is anticipated to be fueled by the expanding mining activities. These operations involve the extraction of valuable minerals, ores, and geological materials from the Earth's crust. Black lung disease, a condition affecting coal miners, is attributed to the inhalation of coal mine dust, which contains hazardous carbon-containing particles. For instance, in January 2022, the United States Geological Survey reported a slight increase in global silver mine production in 2021, rising from 23,500 tons in 2020 to an estimated 24,000 tons. This points to the ongoing expansion of mining activities. Consequently, the rise in mining endeavors is a key driver for the growth of the black lung disease market.

The escalating prevalence of tuberculosis is anticipated to drive the growth of the black lung disease market. Tuberculosis, caused primarily by Mycobacterium tuberculosis, is an airborne bacterial infection transmitted when an infected person coughs or sneezes. It manifests with symptoms like coughing, fever, weight loss, and fatigue. The increasing incidence of tuberculosis is linked to the growth of black lung disease, as individuals with TB face a higher risk of developing black lung disease and are more likely to be exposed to coal dust. For instance, in March 2023, the Centers for Disease Control and Prevention reported 8,300 cases of tuberculosis in the US in 2022, up from 7,874 cases in 2021. Thus, the rising prevalence of tuberculosis is a significant driver behind the growth of the black lung disease market.

A notable hindrance to the growth of the black lung disease market is the prevailing lack of awareness about the disease. This is particularly significant among miners and their families. One primary reason for this challenge is the prolonged development of the disease, which makes early diagnosis a difficult task. For instance, as of December 2021, Wolfe Williams & Reynolds P.C., a US-based social security disability firm, underlined this issue, emphasizing the limited understanding of black lung disease and its associated symptoms, resulting in delayed diagnosis and treatment. Consequently, the existing lack of awareness concerning the disease stands as a substantial barrier to the market's growth.

The growth of the black lung disease market is significantly bolstered by government funding initiatives. These initiatives involve the allocation of financial resources by government bodies, often at federal, state, or local levels, to support a range of activities, programs, projects, and organizations that serve public interests or fulfill specific government objectives. One crucial area of focus for such funding is the protection of coal miners from black lung disease. For instance, in September 2022, according to the US Department of Labor Blog, a US-based government authority, funding for miners with black lung disease was permanently extended with the Inflation Reduction Act of 2022. This act has provided essential and permanent funding for miners and their families affected by black lung disease, ensuring federal black lung benefits. As a result, government funding initiatives play a pivotal role in driving both the black lung disease market and the welfare of miners.

In June 2022, Bristol Myers Squibb, a prominent US-based pharmaceutical company, successfully acquired Turning Point Therapeutics, further solidifying its position in the field of oncology and black lung disease treatment. This strategic move allows Bristol Myers to integrate a cutting-edge, late-stage precision oncology asset into its already robust oncology portfolio. Turning Point Therapeutics, a US-based pharmaceutical company, is currently in the process of developing a drug with potential applications in the treatment of black lung disease.

Major players in the black lung disease market are Pfizer Inc., Johnson and Johnson, Siemens AG, General Electric, F. Hoffmann-La Roche AG, Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Melinta Therapeutics LLC, GlaxoSmithKline PLC, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Toshiba Corporation, Koninklijke Philps N.V., Mayo Clinic, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Lab India Pvt. Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited.

North America was the largest region in the black lung disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in black lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the black lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The disease is categorized into simple coal workers’ pneumoconiosis, complicated coal workers’ pneumoconiosis, and other forms. Simple CWP, often referred to as simple black lung disease, arises from prolonged exposure to coal dust. Treatment options encompass oxygen therapy, bronchodilators, lung transplant, stem cell therapy, and other interventions. Diagnosing the condition involves procedures like biopsy, various imaging techniques, full blood count analysis, pulmonary function tests, physical examination, among others. These diagnostic and treatment approaches are employed across a range of healthcare settings, including hospitals, clinics, research institutions, diagnostic centers, and laboratories.

This report provides black lung disease market statistics, including black lung disease industry global market size, regional shares, competitors with a black lung disease market share, detailed black lung disease market segments, market trends and opportunities and any further data you may need to thrive in the black lung disease industry. This black lung disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The black lung disease market includes revenues earned by entities by providing pulmonary rehabilitation (PR), medical services and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.